Clinical Trial Update: Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study evaluating roginolisib (IOA-244) in combination with venetoclax and rituximab for patients with refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Leukemia

Drugs mentioned

• Rituximab (rituximab)
• Roginolisib (IOA-244) (roginolisib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Jennifer R. Brown, MD, PhD | Conditions: Leukemia, Relapsed Leukemia | Phase 1, Phase 2 | Status: RECRUITING